- Record: found
- Abstract: found
- Article: found
HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration
Pravin U. Dugel ,
Adrian Koh ,
Yuichiro Ogura ,
Glenn Jaffe ,
Ursula Schmidt-Erfurth ,
David Brown ,
Andre V. Gomes ,
James Warburton ,
Andreas Weichselberger ,
Frank G. Holz
April 2019
April 2019
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a
single-chain antibody fragment that inhibits vascular endothelial growth factor-A,
with aflibercept to treat neovascular age-related macular degeneration (nAMD).